<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE collection SYSTEM "BioC.dtd"><collection><source>BioC-API</source><date>20260212</date><key>collection.key</key><document><id>PMC12861554</id><infon key="license">CC BY</infon><passage><infon key="article-id_doi">10.1002/jcsm.70206</infon><infon key="article-id_other">JCSM-D-25-00099</infon><infon key="article-id_pmc">PMC12861554</infon><infon key="article-id_publisher-id">JCSM70206</infon><infon key="elocation-id">e70206</infon><infon key="issue">1</infon><infon key="kwd">aerobic fitness disease activity inflammatory bowel disease muscle strength physical activity quality of life sarcopenia</infon><infon key="license">This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</infon><infon key="name_0">surname:Kasznár;given-names:Emese</infon><infon key="name_1">surname:Csendes;given-names:Barbara</infon><infon key="name_10">surname:Müller;given-names:Katalin Eszter</infon><infon key="name_2">surname:Gergő;given-names:Dorottya</infon><infon key="name_3">surname:Hegyi;given-names:Péter</infon><infon key="name_4">surname:Tóth;given-names:Réka</infon><infon key="name_5">surname:Fogarasi;given-names:András</infon><infon key="name_6">surname:Garami;given-names:Miklós</infon><infon key="name_7">surname:Ocskay;given-names:Klementina</infon><infon key="name_8">surname:Párniczky;given-names:Andrea</infon><infon key="name_9">surname:Obeidat;given-names:Mahmoud</infon><infon key="notes">

, , , et al., “,” 
, no.  (): , .
</infon><infon key="pub-id_doi">10.1002/jcsm.70206</infon><infon key="section_type">TITLE</infon><infon key="source">Journal of Cachexia, Sarcopenia and Muscle</infon><infon key="type">front</infon><infon key="volume">17</infon><infon key="year">2026</infon><offset>0</offset><text>Physical Activity Improves Quality of Life in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta‐Analysis</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>128</offset><text>ABSTRACT</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>137</offset><text>Background</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>148</offset><text>Patients with inflammatory bowel disease (IBD) are often less active physically and experience impaired bone mineral density (BMD) as well as sarcopenia, which are associated with a higher risk of poor disease outcomes. Physical exercise can improve BMD and sarcopenia and may also play a role in controlling inflammation via anti‐inflammatory myokines. This study aimed to evaluate the effects of structured physical exercise on the disease activity and quality of life of patients with IBD by conducting a before‐and‐after analysis.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>689</offset><text>Methods</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>697</offset><text>We conducted a systematic search on 16 November 2023. Studies with structured exercise interventions in patients with IBD focusing on quality of life, disease activity, body composition, muscle strength, inflammatory markers, aerobic fitness and sedentary time were included. The mean difference (MD) or the standardized MD (SMD) of the differences between the before and after values was used to measure the effect size with a 95% confidence interval (CI). Risk of bias was assessed using the MINORS tool.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1204</offset><text>Results</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1212</offset><text>Twenty‐one studies involving 498 patients with IBD were included. Quality of life improved significantly: SMD 0.55 (CI, 0.30–0.80), particularly in the systemic subscale. Disease activity scores showed a non‐significant improvement: SMD −0.20 (CI, −0.47 to 0.07) in Crohn's disease and SMD −0.23 (CI, −0.46 to 0.00) in ulcerative colitis. Numbers of inflammatory markers and faecal calprotectin levels also improved, but not significantly. Muscle strength and aerobic fitness improved, with a significant increase in VO2 max: SMD 1.88 (CI, 1.34–2.43). Due to the lack of available data, we were unable to conduct a statistical analysis of body composition parameters and sedentary time.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1915</offset><text>Conclusion</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1926</offset><text>Regular physical activity improves quality of life and physical fitness of IBD patients, with potential benefits for disease activity and sarcopenia.</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">title</infon><offset>2076</offset><text>Abbreviations</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2090</offset><text>BFM</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2094</offset><text>body fat mass</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2108</offset><text>BMD</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2112</offset><text>bone mineral density</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2133</offset><text>CD</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2136</offset><text>Crohn's disease</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2152</offset><text>CDAI</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2157</offset><text>Crohn's disease activity index</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2188</offset><text>CI</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2191</offset><text>confidence interval</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2211</offset><text>CRP</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2215</offset><text>C‐reactive protein</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2236</offset><text>ESR</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2240</offset><text>erythrocyte sedimentation rate</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2271</offset><text>HRQoL</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2277</offset><text>health‐related quality of life</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2310</offset><text>IBD</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2314</offset><text>inflammatory bowel disease</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2341</offset><text>LBM</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2345</offset><text>lean body mass</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2360</offset><text>MD</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2363</offset><text>mean difference</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2379</offset><text>MINORS</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2386</offset><text>methodological index for non‐randomized studies</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2436</offset><text>PCDAI</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2442</offset><text>paediatric Crohn's disease activity index</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2484</offset><text>PUCAI</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2490</offset><text>paediatric ulcerative colitis activity index</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2535</offset><text>QoL</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2539</offset><text>quality of life</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2555</offset><text>SMD</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2559</offset><text>standardized mean difference</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2588</offset><text>SMM</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2592</offset><text>skeletal muscle mass</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2613</offset><text>UC</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2616</offset><text>ulcerative colitis</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2635</offset><text>VO2 peak</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>2644</offset><text>maximal oxygen uptake</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>2666</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2679</offset><text>The prevalence of inflammatory bowel disease (IBD) represents a significant public health concern, characterized by a rising number of patients with increased risk for mortality and disability‐adjusted life‐years. In 2019, approximately 4.9 million individuals worldwide were diagnosed with IBD, and 147 out of 204 countries or territories reported an increase in the age‐standardized prevalence rate. Approximately 15%–25% of patients are diagnosed with IBD during childhood, and as IBD is an incurable, lifelong disease, it is essential to reduce the disease burden without escalating medication use.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3290</offset><text>Patients with IBD tend to exhibit reduced levels of physical activity as a consequence of their symptoms. Some data indicate that they live a more sedentary life even when in remission compared with healthy people. Their disease and lack of physical activity lead to decreased bone mineral density (BMD), muscle mass and function. A recent review has demonstrated that sarcopenia in patients with IBD is significantly associated with an increased risk of therapy failure, postoperative complications and low BMD.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3803</offset><text>It is important to recognize that IBD affects both the body and the mind, both of which play an important role in quality of life (QoL). Health‐related QoL (HRQoL) is a multi‐dimensional concept and a useful indicator of overall health, as it provides information on an individual's physical and mental health status, social relationships and personal beliefs. There is a bidirectional association between IBD and mental health status, and both of them have a critical impact on QoL. A review published in 2021 found that both depression and anxiety tend to influence disease activity, trigger flares and increase healthcare utilization in patients with IBD.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4466</offset><text>Similarly, physical activity also affects the body and the mind. It is known to improve mood and reduce stress in healthy individuals, contributing to better QoL, and its benefits are being increasingly explored in the context of chronic diseases.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4714</offset><text>In a previous systematic review and meta‐analysis on this topic, the authors found that physical activity can have beneficial effects on reducing disease activity and improving QoL when they compared adult patients with IBD and healthy controls with structured exercise interventions for at least 4 weeks. However, it remains unclear whether this improvement is clinically meaningful and how it affects children. The objective of this study was to conduct a before‐and‐after analysis to evaluate the effects of structured physical exercise on patients with IBD, irrespective of age or disease activity.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>5325</offset><text>Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5333</offset><text>The systematic review and meta‐analysis followed the Cochrane Handbook and adhered to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) 2020 statement (Table S1). The study protocol was registered in advance on PROSPERO (CRD42023483457), and we adhered to it.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>5628</offset><text>Eligibility Criteria</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5649</offset><text>The study population consisted of both paediatric and adult patients with IBD who received structured exercise interventions in addition to standard care. The exercise interventions included physical activities such as walking, running, cycling, resistance and endurance training, yoga and exergames. We did not exclude trials that included dietary advice or supplements in addition to exercise. The primary outcomes were QoL and disease activity scores. Secondary outcomes were body composition: BMD, lean body mass/fat‐free mass (LBM), skeletal muscle mass (SMM) and body fat mass (BFM); muscle strength: handgrip strength (HGS), planking and isometric muscle strength; inflammatory markers: faecal calprotectin, C‐reactive protein (CRP) and erythrocyte sedimentation rate (ESR); aerobic fitness: maximal oxygen uptake (VO2 peak); and sedentary time. The study included randomized controlled trials (RCTs), non‐randomized trials, cohort studies, case–control studies, pilot studies, conference abstracts and case series. However, case reports were excluded to maintain objectivity and to avoid subjective evaluations.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6777</offset><text>Information Sources</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6797</offset><text>On 16 November 2023, a systematic search was conducted on three databases: EMBASE, PubMed and Cochrane Central Register of Controlled Trials (CENTRAL). In addition, a backward and forward citation search was performed using a reference‐checking tool to identify all potential references.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>7087</offset><text>Search Strategy</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7103</offset><text>The search key comprised two domains: IBD and physical interventions. No limits were set for the publication period, and no language or other restrictions were applied during the search (Table S2).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>7302</offset><text>Selection Process</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7320</offset><text>The studies were imported into the reference management software, EndNote 20. After the automatic and manual removal of duplicates, two independent authors conducted title–abstract selection (E.K. and B.C.) and subsequently screened the full texts. Disagreements were resolved after a discussion with a third author (D.G.). The Cohen's kappa coefficient was calculated after each selection phase.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>7719</offset><text>Data Collection Process</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7743</offset><text>Data from eligible studies were extracted by two independent researchers (E.K. and B.C.) using an Excel data collection form Office 365 by Microsoft. Any questions or discrepancies related to data extraction were resolved through discussion.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>7985</offset><text>Data Items</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7996</offset><text>Data extracted from the studies included first author, year of publication, digital object identifier, study design, study period, country, number of participating centres, total number of patients, age of the population, sex distribution, IBD type, disease activity status, exercise intervention, length of intervention, frequency of the intervention, time of measurements, QoL and disease activity scores, BMD, LBM or FFM, SMM, BFM, HGS, planking, isometric muscle strength, faecal calprotectin, CRP, ESR, VO2 peak and sedentary time.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>8533</offset><text>Study Risk of Bias Assessment</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8563</offset><text>The risk of bias assessment for each study was independently performed by two investigators (E.K. and B.C.) using the methodological index for non‐randomized studies (MINORS) tool. Disagreements were resolved through discussion. The study evaluated the eight items of the MINORS and conducted an overall bias assessment based on (1) a clearly stated aim, (2) inclusion of consecutive patients, (3) prospective data collection, (4) appropriate endpoints, (5) unbiased assessment of the study endpoint, (6) appropriate follow‐up period, (7) loss to follow‐up less than 5% and (8) prospective calculation of study size.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>9186</offset><text>Synthesis Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9204</offset><text>All statistical analyses were conducted using R with the meta package, using random‐effects models. The mean of the differences between the measurements before and after the intervention was used as the effect size measure. Sample size, mean and corresponding standard deviation (SD) of the measurements before and after the intervention were extracted (separately by the reported subgroup). Standard errors (SE), confidence intervals (CI), medians, interquartile ranges (IQR), minima and maxima were also extracted. If the same data were directly available for the difference, they were also extracted, as well as t or p values from the paired t‐tests. To calculate the SDs from the CI or p values, we assumed a t distribution. To estimate means and SDs from medians and IQR and/or range, we used the Luo and Shi methods, as implemented in the meta package.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>10067</offset><text>MDs were used when studies assessed the same outcome with the same measurement units, allowing direct comparison of raw score changes. For studies using different instruments to assess the same construct (e.g., HRQoL questionnaires and disease activity indices), SMDs were calculated by dividing the mean change score (post‐intervention minus baseline) by the baseline SD, as recommended by Harrer et al. to standardize effect sizes across scales. We also clarified that pooled estimates were calculated using inverse‐variance weighting under a random‐effects model, and heterogeneity was quantified using τ 2 from the restricted maximum‐likelihood estimator with the Q‐profile method for CIs.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>10773</offset><text>We estimated the correlation coefficient between the before and after values based on the extracted, calculated or estimated SD of the change when the SD for the baseline and after‐treatment value was also available. If this resulted in a value above one or a negative value, we did not use it. Without information on the SD of the change, the change in the SD was calculated for all studies that used the average of the remaining correlation coefficients for the given outcome. If no other correlation coefficients were available, a value of 0.6 was assumed. The sensitivity analysis used coefficients between 0.1 and 0.9 instead of the average or the default, leading to almost identical results.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>11474</offset><text>We used a Hartung–Knapp adjustment for the CIs. For subgroup analysis, we used a fixed‐effects ‘plural’ model (aka mixed‐effects model). To assess the difference between the subgroups, we used a ‘Cochrane Q’ test (an omnibus test) between subgroups. We summarized meta‐analysis findings in forest plots.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>11794</offset><text>In order to guarantee the accuracy and reliability of the synthesis, every study that provided sufficient data was included. Conversely, studies that lacked sufficient data were excluded.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>11982</offset><text>We planned subgroup analysis for each outcome based on disease type (CD vs. UC), age group (children vs. adults) and disease activity (active disease vs. remission).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>12148</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>12156</offset><text>Search and Selection</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12177</offset><text>A total of 13 070 records were identified in the systematic search. After title and abstract selection, we found 714 eligible studies during the full‐text selection, of which 21 were included in the quantitative analysis (Figure 1).</text></passage><passage><infon key="file">JCSM-17-e70206-g002.jpg</infon><infon key="id">jcsm70206-fig-0001</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>12415</offset><text>PRISMA 2020 flowchart representing the study selection process.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>12479</offset><text>Basic Characteristics of Studies Included</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12521</offset><text>The characteristics of the studies included are summarized in Table 1. Of the 21 included studies, 10 were RCTs and 11 were uncontrolled before–after studies. The studies involved 498 patients with IBD (56% female). Twelve studies included patients with both Crohn's disease (CD) and ulcerative colitis (UC), seven included only patients with CD, one included only patients with UC and one did not specify the disease type. Participants were described as in remission, with inactive to mildly active disease and mild to moderately active disease, and three studies did not specify disease activity . Six studies were conducted in a paediatric population with a minimum age of 6 years and maximum age of 21 years; and 15 in the adult population.</text></passage><passage><infon key="file">jcsm70206-tbl-0001.xml</infon><infon key="id">jcsm70206-tbl-0001</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>13274</offset><text>Characteristics of studies included in the meta‐analysis and systematic review.</text></passage><passage><infon key="file">jcsm70206-tbl-0001.xml</infon><infon key="id">jcsm70206-tbl-0001</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;col align=&quot;left&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;center&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;center&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;center&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;center&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;center&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;center&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;center&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;center&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;center&quot; span=&quot;1&quot;/&gt;&lt;thead valign=&quot;bottom&quot;&gt;&lt;tr style=&quot;border-bottom:solid 1px #000000&quot;&gt;&lt;th align=&quot;left&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Study (first author, year)&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Country&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Study design&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Age group&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Participants (n)&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Disease types&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Disease status&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Intervention&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Length of intervention&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Outcome measures&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody valign=&quot;top&quot;&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Arruda, 2018&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;USA&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Prospective, non‐randomized pilot study&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Paediatric&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CD and UC&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Remission&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yoga&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8 weeks, 3–4 times/week for 30–60 min&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Disease activity index, faecal calprotectin&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Bjelica, 2023&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Canada&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pilot study&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Paediatric&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CD and UC&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Remission&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Aerobic and resistance training + high protein beverage after every session&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;16 weeks, 3 times/week for 30–60 min&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;BMD, BFM, LBM, HGS, VO&lt;sub&gt;2&lt;/sub&gt; peak, sedentary time&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Legeret, 2019&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Switzerland&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case–control intervention study&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Paediatric&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;21&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CD, UC and IBD‐U&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Active and remission&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Exergames&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8 weeks, 5 times/week for 30 min&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Disease activity index, CRP, ESR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Mählmann, 2017&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Switzerland&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case–control intervention study&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Paediatric&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;21&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CD and UC&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Active and remission&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Exergames&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9 weeks, 5 times/week for 30 min&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Sedentary time&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Scheffers, 2023&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;The Netherlands&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Prospective single‐center randomized semi‐crossover controlled trial&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Paediatric&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;15&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CD and UC&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Active and remission&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Personalized aerob and resistance training + personalized healthy dietary advice&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12 weeks, 2–3 times/week for 60 min&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;QoL, disease activity index, faecal calprotectin, CRP, ESR, BFM, HGS, sedentary time&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Trivić, 2023&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Croatia&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pre–post interventional study&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Paediatric&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;42&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CD, UC and IBD‐U&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Remission&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Personalized, home‐based structured exercise programme&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;26 weeks, 3 times/week&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Faecal calprotectin, CRP, BMD, BFM, LBM, sedentary time&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cramer, 2017&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Germany&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Single‐blind randomized controlled trial&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;39&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;UC&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Remission&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yoga&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12 weeks, 1/week for 90 min&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;QoL, disease activity score, faecal calprotectin, CRP, ESR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cronin, 2019&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Ireland&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Randomized, partial cross‐over trial&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;13&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CD and UC&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Remission&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Aerobic and resistance training&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8 weeks&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;QoL, disease activity score, CRP, LBM, BFM, VO&lt;sub&gt;2&lt;/sub&gt; peak&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Jones, 2020&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;UK&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Two‐arm, randomized, parallel‐group and assessor‐blind trial&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;23&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CD&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Remission&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Impact and high‐effort resistance exercises&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;26 weeks, 3 times/week for 60 min&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;QoL, BMD, HGS&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Kaur, 2021&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Canada&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pre‐ and post‐intervention pilot study&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CD and UC&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Active and remission&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yoga + meditation, breathing and lavender oil foot massage&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8 weeks, 7 times/week for 30 min&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;QoL, disease activity score&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Klare, 2015&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Germany&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Prospective randomized controlled trial&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;15&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CD and UC&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Remission&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Running&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10 weeks, 3 times/week&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;QoL, disease activity score, faecal calprotectin, CRP&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Loudon, 1999&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Canada&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pilot study&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CD&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Active and remission&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Walking&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12 weeks, 3 times/week for 20–35 min&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;QoL, disease activity score, VO&lt;sub&gt;2&lt;/sub&gt;peak&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Ng, 2007&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Canada&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Randomized prospective study&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;16&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CD&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Remission&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Walking&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12 weeks, 3 times/week for 30 min&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;QoL, disease activity score&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Robinson, 1998&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;UK&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;RCT&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;60&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CD&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Remission&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Home‐based, low‐impact exercises&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;52 weeks, 2 times/week&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Disease activity score, BMD&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Seeger, 2020&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Germany&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pilot three‐arm parallel group RCT&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;22&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CD&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Remission&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Endurance/muscle training&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12 weeks, 3 times/week for 30–40 min&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;QoL, disease activity score, faecal calprotectin, HGS&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Tew, 2019&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;UK&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pilot RCT&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;25&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CD&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Remission&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;High intensity/moderate intensity interval training&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12 weeks, 3 times/week for 28–38 min&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;QoL, disease activity score, faecal calprotectin, VO&lt;sub&gt;2&lt;/sub&gt;peak&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;van Erp, 2021&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;The Netherlands&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pilot study&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;25&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CD, UC and IBD‐U&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Remission&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Personalized exercise programme with aerobic training and progressive resistance training&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12 weeks, 3 times/week for 60 min&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;QoL, BFM, VO&lt;sub&gt;2&lt;/sub&gt;peak&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Zhao, 2022&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Randomized, double‐blind, placebo‐controlled trial&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;13&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;N/A&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Active and remission&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Resistance training&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8 weeks, 3 times/week&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CRP, ESR, SMM, HGS&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;de Souza, 2014&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Brazil&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Abstract&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;19&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CD and UC&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;N/A&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Quadriceps progressive resistance training&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8 weeks, 2 times/week for 20 min&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;QoL, quadriceps strength&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fagan, 2019&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;New Zealand&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Abstract&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;59&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CD and UC&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;N/A&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;N/A&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;17 weeks, 5 times/week for 10 min&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;QoL, disease activity score&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fischbach, 2009&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Germany&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Abstract&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;30&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CD&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;N/A&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;N/A&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12 weeks, 2 times/week for 90 min&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;QoL, disease activity score&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>13356</offset><text>Study (first author, year)	Country	Study design	Age group	Participants (n)	Disease types	Disease status	Intervention	Length of intervention	Outcome measures	 	Arruda, 2018	USA	Prospective, non‐randomized pilot study	Paediatric	9	CD and UC	Remission	Yoga	8 weeks, 3–4 times/week for 30–60 min	Disease activity index, faecal calprotectin	 	Bjelica, 2023	Canada	Pilot study	Paediatric	10	CD and UC	Remission	Aerobic and resistance training + high protein beverage after every session	16 weeks, 3 times/week for 30–60 min	BMD, BFM, LBM, HGS, VO2 peak, sedentary time	 	Legeret, 2019	Switzerland	Case–control intervention study	Paediatric	21	CD, UC and IBD‐U	Active and remission	Exergames	8 weeks, 5 times/week for 30 min	Disease activity index, CRP, ESR	 	Mählmann, 2017	Switzerland	Case–control intervention study	Paediatric	21	CD and UC	Active and remission	Exergames	9 weeks, 5 times/week for 30 min	Sedentary time	 	Scheffers, 2023	The Netherlands	Prospective single‐center randomized semi‐crossover controlled trial	Paediatric	15	CD and UC	Active and remission	Personalized aerob and resistance training + personalized healthy dietary advice	12 weeks, 2–3 times/week for 60 min	QoL, disease activity index, faecal calprotectin, CRP, ESR, BFM, HGS, sedentary time	 	Trivić, 2023	Croatia	Pre–post interventional study	Paediatric	42	CD, UC and IBD‐U	Remission	Personalized, home‐based structured exercise programme	26 weeks, 3 times/week	Faecal calprotectin, CRP, BMD, BFM, LBM, sedentary time	 	Cramer, 2017	Germany	Single‐blind randomized controlled trial	Adult	39	UC	Remission	Yoga	12 weeks, 1/week for 90 min	QoL, disease activity score, faecal calprotectin, CRP, ESR	 	Cronin, 2019	Ireland	Randomized, partial cross‐over trial	Adult	13	CD and UC	Remission	Aerobic and resistance training	8 weeks	QoL, disease activity score, CRP, LBM, BFM, VO2 peak	 	Jones, 2020	UK	Two‐arm, randomized, parallel‐group and assessor‐blind trial	Adult	23	CD	Remission	Impact and high‐effort resistance exercises	26 weeks, 3 times/week for 60 min	QoL, BMD, HGS	 	Kaur, 2021	Canada	Pre‐ and post‐intervention pilot study	Adult	9	CD and UC	Active and remission	Yoga + meditation, breathing and lavender oil foot massage	8 weeks, 7 times/week for 30 min	QoL, disease activity score	 	Klare, 2015	Germany	Prospective randomized controlled trial	Adult	15	CD and UC	Remission	Running	10 weeks, 3 times/week	QoL, disease activity score, faecal calprotectin, CRP	 	Loudon, 1999	Canada	Pilot study	Adult	12	CD	Active and remission	Walking	12 weeks, 3 times/week for 20–35 min	QoL, disease activity score, VO2peak	 	Ng, 2007	Canada	Randomized prospective study	Adult	16	CD	Remission	Walking	12 weeks, 3 times/week for 30 min	QoL, disease activity score	 	Robinson, 1998	UK	RCT	Adult	60	CD	Remission	Home‐based, low‐impact exercises	52 weeks, 2 times/week	Disease activity score, BMD	 	Seeger, 2020	Germany	Pilot three‐arm parallel group RCT	Adult	22	CD	Remission	Endurance/muscle training	12 weeks, 3 times/week for 30–40 min	QoL, disease activity score, faecal calprotectin, HGS	 	Tew, 2019	UK	Pilot RCT	Adult	25	CD	Remission	High intensity/moderate intensity interval training	12 weeks, 3 times/week for 28–38 min	QoL, disease activity score, faecal calprotectin, VO2peak	 	van Erp, 2021	The Netherlands	Pilot study	Adult	25	CD, UC and IBD‐U	Remission	Personalized exercise programme with aerobic training and progressive resistance training	12 weeks, 3 times/week for 60 min	QoL, BFM, VO2peak	 	Zhao, 2022	China	Randomized, double‐blind, placebo‐controlled trial	Adult	13	N/A	Active and remission	Resistance training	8 weeks, 3 times/week	CRP, ESR, SMM, HGS	 	de Souza, 2014	Brazil	Abstract	Adult	19	CD and UC	N/A	Quadriceps progressive resistance training	8 weeks, 2 times/week for 20 min	QoL, quadriceps strength	 	Fagan, 2019	New Zealand	Abstract	Adult	59	CD and UC	N/A	N/A	17 weeks, 5 times/week for 10 min	QoL, disease activity score	 	Fischbach, 2009	Germany	Abstract	Adult	30	CD	N/A	N/A	12 weeks, 2 times/week for 90 min	QoL, disease activity score	 	</text></passage><passage><infon key="file">jcsm70206-tbl-0001.xml</infon><infon key="id">jcsm70206-tbl-0001</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>17540</offset><text>Abbreviations: BFM = body fat mass; BMD = bone mineral density; CD = Crohn's disease; CRP = C‐reactive protein; ESR = erythrocyte sedimentation rate; HGS = handgrip strength; IBD‐U = inflammatory bowel disease unclassified; LBM = lean body mass; QoL = quality of life; SMM = skeletal muscle mass; UC = ulcerative colitis.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>17910</offset><text>Improvement of Disease‐Specific HRQoL</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>17950</offset><text>Eight studies reported data using the disease‐specific IBDQ, and one used the short version of the IBDQ. Furthermore, another study utilized the disease‐specific IMPACT‐III developed for children. Data from 169 patients revealed a statistically significant improvement in QoL following interventions (SMD 0.55 [CI, 0.30–0.80, I 2 = 59%, CI, 15%–80%, p &lt; 0.001]) (Figure 2).</text></passage><passage><infon key="file">JCSM-17-e70206-g004.jpg</infon><infon key="id">jcsm70206-fig-0002</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>18343</offset><text>Impact of physical exercise on disease‐specific health‐related quality of life. CI = confidence interval; HRQoL = health‐related quality of life; IBD = inflammatory bowel disease; IBDQ = inflammatory bowel disease questionnaire; N = number of patients; SD = standard deviation; sIBDQ = short version of inflammatory bowel disease questionnaire; SMD = standardized mean difference.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>18762</offset><text>One study that used the IBDQ could not be included due to missing data . However, Fagan et al. reported that 31% of participants experienced clinically meaningful improvement. All studies applying general HRQoL instruments utilized the SF‐36 and SF‐12 for QoL data and showed significant or non‐significant improvements (p &lt; 0.05).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>19106</offset><text>All subscale analyses of the bowel, emotional, social, and systemic subscales showed an increase in HRQoL (Figure S1).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>19226</offset><text>Change in Disease Activity Score</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>19259</offset><text>Fourteen studies assessed disease activity scores, involving 212 patients with CD and 105 patients with UC. To measure CD activity, we included studies that used the CDAI, Harvey Bradshaw Index/Simple Index of Crohn's Disease Activity  and PCDAI. For UC activity, we included studies that used the Rachmilewitz Index, Simple Colitis Index, Partial Mayo Score and PUCAI. The effect size showed a tendency for improvement both in the CD and UC group (CD: SMD: −0.20 [CI, −0.47 to 0.07, I 2 = 62%, CI, 30%–80%, p = 0.131] and UC: SMD −0.23 [CI, −0.46 to 0.00, I 2 = 61%, CI, 16%–82%, p = 0.053]) (Figure 3a,b).</text></passage><passage><infon key="file">JCSM-17-e70206-g003.jpg</infon><infon key="id">jcsm70206-fig-0003</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>19897</offset><text>(a) Change in Crohn's disease activity score during physical exercise. (b) Change in ulcerative colitis disease activity score during physical exercise. CDAI = Crohn's disease activity index; CI = confidence interval; N = number of patients; PCDAI = paediatric Crohn's disease activity index; HBI = Harvey–Bradshaw Index; SD = standard deviation; SMD = standardized mean difference.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>20310</offset><text>Impact of Physical Exercise on Levels of Inflammatory Markers</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>20372</offset><text>Six studies reported alteration in CRP levels, and four reported ESR changes. The MD for both parameters decreased, though the difference was not statistically significant (CRP: MD −0.13 [CI, −0.30 to 0.03, I 2 = 47%, CI, 0%–79%, p = 0.096] and ESR: MD −6.21 [CI, −13.31 to 0.90, I 2 = 91%, CI, 80%–96%, p = 0.069]) (Figures S2 and S3). Faecal calprotectin was measured in six studies and the MD was −101.57 (CI, −417.91 to 214.77, I 2 = 69%, CI, 12%–89%, p = 0.382) (Figure 4).</text></passage><passage><infon key="file">JCSM-17-e70206-g005.jpg</infon><infon key="id">jcsm70206-fig-0004</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>20895</offset><text>Shift in faecal calprotectin levels during structured physical exercise. CD = Crohn's disease; CI = confidence interval; IBD = inflammatory bowel disease; N = number of patients; SD = standard deviation; UC = ulcerative colitis; Δmean = mean difference.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>21178</offset><text>Changes in Muscle Strength</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>21205</offset><text>HGS was measured in two paediatric and three adult studies. Data from 73 patients showed a non‐significant increase (SMD: 0.38 [CI, −0.14 to 0.90, I 2 = 72%, CI, 30%–89%, p = 0.115]) (Figure 5). Quadriceps strength was reported in three studies with an SMD of 0.75 (CI, −1.58 to 3.08, I 2 = 93%, CI, 84%–97%, p = 0.302) (Figure S4).</text></passage><passage><infon key="file">JCSM-17-e70206-g001.jpg</infon><infon key="id">jcsm70206-fig-0005</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>21566</offset><text>Impact of physical exercise on handgrip strength. CD = Crohn's disease; CI = confidence interval; IBD = inflammatory bowel disease; N = number of patients; SD = standard deviation; SMD = standardized mean difference.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>21807</offset><text>Improvement in Aerobic Fitness</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>21838</offset><text>VO2 measurements significantly improved based on the result of two studies involving children and three studies involving adults, including 70 patients (MD 1.88 [CI, 1.34–2.43, I 2 = 0%, CI, 0%–79%, p &lt; 0.001]) (Figure S5).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>22075</offset><text>Body Composition During Structured Physical Exercise: Qualitative Synthesis</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>22151</offset><text>Five studies evaluated BFM, by employing diverse methodologies for body composition assessment, including dual‐energy X‐ray absorptiometry and skinfold thickness measurements. Of the studies identified, two were conducted in adult populations, and three were conducted in paediatric populations. The results of two studies indicated an increase in BFM, whereas the other three reported a decrease.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>22553</offset><text>LBM was assessed in three studies; despite the use of identical measurement tools, the data could not be analysed due to heterogeneous data presentation (Z‐scores, raw values and percentages). The results of the three studies indicate an improving trend as a result of physical intervention, although only two were statistically significant.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>22897</offset><text>BMD was reported in two paediatric and two adult studies. All four studies showed an improvement in BMD, although only one study reported a significant increase.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>23059</offset><text>SMM was measured in only one study, which found that height‐adjusted appendicular SMM significantly improved as the intervention progressed.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>23202</offset><text>Change in Sedentary Time</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>23227</offset><text>Sedentary time was measured in only three studies. Data, however, could not be pooled due to the different data reporting methods. Two studies showed a trend towards a reduction in sedentary time after the intervention. The third, however, did not.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>23476</offset><text>The Role of Exercise Type</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>23502</offset><text>Participants in five studies engaged in aerobic exercises, whereas four studies focused on resistance training. In addition, five studies involved low‐intensity workouts. Finally, four studies employed a combination of mixed exercises, which included both aerobic and resistance training. We planned to compare each outcome by exercise type, but the data were not sufficient to perform an accurate analysis. However, the data did not suggest a difference in the QoL by exercise type (Figure S6).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>24001</offset><text>Risk of Bias Assessment</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>24025</offset><text>The detailed results of the risk of bias assessment are presented in Table S3. Of the studies included, three had a low overall risk of bias, eight had a moderate risk and ten had a high risk. The most common reason for the moderate risk of bias was the absence of a prospective study size calculation. The high risk of bias was typically due to the same underlying issue, combined with a loss to follow‐up of more than 5%. Other causes of high risk included unclear definitions of inclusion/exclusion criteria and an inadequate follow‐up period (more than 12 weeks after initial measurement).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>24626</offset><text>Publication Bias and Heterogeneity</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>24661</offset><text>Between‐study heterogeneity was described using Higgins and Thompson's I 2 statistics. High heterogeneity in muscle strength and inflammatory markers (CRP, ESR and faecal calprotectin) is likely to arise from methodological and biological variability. In the case of muscle strength, differences in assessment methods, testing protocols, equipment and participant characteristics (e.g., age, sex, nutritional status and baseline activity levels) can influence the results obtained. Inflammatory markers are subject to natural fluctuations and variations in baseline disease activity. They are also affected by differences between IBD subtypes and the effects of concurrent medications, particularly corticosteroids or biologics. Further inconsistency is introduced by additional variability in laboratory assays and cut‐off values, which can potentially obscure the true impact of structured exercise on these outcomes.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>25585</offset><text>Small study publication bias was assessed by visual inspection of funnel plots if there were at least 5 studies and Egger's test if there were at least 10 studies. We considered possible small study bias if the p value was less than 0.1. The funnel plot could be assessed for HRQoL, CRP, aerobic fitness, HGS and disease activity scores and revealed publication bias in the case of HRQoL, HGS and disease activity scores (Figures S7–S11). The publication bias in these outcomes can be explained by several factors. Smaller trials of structured exercise for IBD have less control over confounding factors, and these trials/studies often end up reporting larger improvements, which are sometimes due to chance. Different HRQoL instruments, HGS protocols and disease activity scores can produce inconsistent results. Smaller or less rigorous studies may select methods that are more likely to demonstrate significant change, thereby inflating effect estimates.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>26546</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>26557</offset><text>In this study, we summarized the association between structured physical exercise and objective and subjective outcomes in patients with IBD. Using the before–after approach, we were able to present the changes in the outcomes investigated over a few weeks of exercise. Our findings indicated a significant improvement in HRQoL, with the most substantial gains observed in the systemic subscale. This means the greatest improvements were in fatigue, energy levels, sleep quality and general health. Furthermore, muscle strength and aerobic fitness improved significantly. Although there was a trend towards improvement in disease activity scores and inflammatory markers (CRP, ESR and faecal calprotectin), these changes were not statistically significant. Although a meta‐analysis was not feasible for some outcomes, preliminary evidence suggests that exercise is associated with a decrease in BFM and an increase in LBM, BMD, SMM and sedentary time.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>27513</offset><text>Similar to the findings of a previous meta‐analysis by Jones et al., the results of our study indicated that HRQoL improved with regular physical exercise. The subscale analysis demonstrated that moderate improvements could be attained in both the systemic and emotional subscales, even though 75% of the patients were in remission or had mildly active disease with relatively high HRQoL at the beginning of some studies.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>27938</offset><text>Disease activity scores non‐significantly decreased in patients with CD and UC. This lack of significance is likely due to the limited potential for improvement. More than half of the analysed studies excluded patients with active disease; as a result, baseline activity scores were low with less likelihood to improve. Furthermore, many of the studies that included patients with active disease did not report separately the data of participants with active and inactive disease. Consequently, a subgroup analysis based on disease activity was not possible.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>28499</offset><text>Our analysis showed that inflammatory markers decreased during the intervention, although the difference was not significant. We observed more pronounced changes in studies that included patients with active disease. However, it is essential to note that CRP levels were only slightly elevated in one study, and ESR levels were within the normal range in all four studies. These findings are consistent with previous reviews. This trend may reflect a modest anti‐inflammatory effect of structured exercise, which larger and longer trials may be better positioned to detect. We also acknowledge that variation in exercise protocols, particularly in terms of intensity, duration and type of exercise, may influence the responsiveness of these markers. For example, higher‐intensity or longer‐duration interventions may produce greater systemic and mucosal anti‐inflammatory effects, whereas shorter or lower‐intensity programmes may be insufficient to generate measurable changes in these biomarkers. Future trials would also benefit from including participants with moderate or severe active disease to better assess the impact of interventions on disease activity and inflammatory markers.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>29699</offset><text>We also planned to perform subgroup analysis by age group, disease activity, intervention type and diagnosis. However, data were not sufficient for these analyses. Only a few paediatric studies assessed these outcomes, and many of the included studies, even those involving the adult population, did not report the data separately based on the planned subgroups (active and inactive patients, or patients with CD and UC). It is noteworthy that the paediatric studies showed similar changes in all outcomes compared with adults (Figure 3b). Most studies included patients in remission or with mild activity and did not report specific results based on activity. Results were similar in studies with patients in remission and mild disease activity. Disease activity and inflammatory markers did not worsen. Additionally, the majority of studies reported no relapses during the intervention period, suggesting that the physical intervention did not cause disease flare‐ups. This has important implications for clinical practice: patients with mild disease may also benefit from exercise. The optimal type of exercise for patients with IBD remains uncertain, as variability in the type and duration of interventions prevented a definitive analysis. Nonetheless, all interventions showed positive effects across outcomes, with none leading to a decline. Although it is still unclear which form of physical activity is most effective in improving the well‐being of patients with IBD, existing evidence indicates that all interventions have been associated with some level of benefit.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>31282</offset><text>Strengths and Limitations</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>31308</offset><text>One of the strengths of our analysis is the comparison of changes to baseline measurements, which demonstrates the benefits of exercise at the individual patient level. In addition, we analysed patients with IBD based on their disease activity separately. Furthermore, a comprehensive analysis of objective and subjective parameters associated with the beneficial effects of physical activity was conducted. Due to the heterogeneity of the interventions, including variations in duration, type, supervision and co‐interventions (e.g., dietary), the analysis was further complicated by the fact that the outcomes were reported in various units of measurement. Additionally, due to the limited number of studies on the paediatric population, it was not feasible to analyse the data separately by age group. Alongside the aforementioned factors, most exercise interventions were of relatively short duration, and several studies excluded patients with active disease. These factors may limit our ability to detect sustained effects and reduce the generalizability of our findings to patients with more severe disease activity.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>32434</offset><text>Implications for Practice and Research</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>32473</offset><text>Our results suggest that physicians should encourage patients with IBD, irrespective of whether they are in remission or have mild disease activity, to engage in regular physical activity. This may include walking, cycling or resistance training, which should be tailored to the fitness level and disease state of the patient. Physical activity should be incorporated into a broader, multidisciplinary guideline that also addresses nutrition, mental health support and regular medical evaluations.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>32971</offset><text>We recommend that future studies include patients with active disease and increase the focus on the paediatric population, as IBD is a lifelong condition, with 25% of patients diagnosed in childhood. We also advise researchers to provide detailed descriptions of interventions and report outcomes using commonly accepted units of measurement. Our findings suggest that the next step in physical activity research on patients with IBD should be to explore the most beneficial forms of exercise for this population.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>33485</offset><text>Conclusions</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>33497</offset><text>Our results suggest that regular physical activity in patients with IBD significantly improves HRQoL and overall physical condition. Furthermore, disease activity scores and inflammatory markers tend to decrease, even among patients in remission. It was not possible to conduct a statistical analysis to ascertain the effect of exercise on body composition. However, the extant data suggest that exercise exerts a positive effect on these parameters. Based on our findings, patients with IBD in remission and mild activity should be encouraged to engage in regular physical activity. Further research is required to identify the most beneficial forms of exercise for this population.</text></passage><passage><infon key="section_type">ACK_FUND</infon><infon key="type">title_1</infon><offset>34181</offset><text>Funding</text></passage><passage><infon key="section_type">ACK_FUND</infon><infon key="type">paragraph</infon><offset>34189</offset><text>Funding was provided by the János Bolyai Research Scholarship of the Hungarian Academy of Sciences (BO/00693/25/5), by the ÚNKP‐23‐5‐SE22 New National Excellence Program of the Ministry for Culture and Innovation from the source of the National Research, Development and Innovation Fund and by the 2024‐2.1.2‐EKÖP‐KDP New National Excellence Program of the Ministry for Culture and Innovation from the source of the National Research, Development and Innovation Fund.</text></passage><passage><infon key="section_type">ACK_FUND</infon><infon key="type">paragraph</infon><offset>34672</offset><text>Sponsors had no role in the design, data collection, analysis, interpretation and manuscript preparation.</text></passage><passage><infon key="section_type">ACK_FUND</infon><infon key="type">title_1</infon><offset>34778</offset><text>Ethics Statement</text></passage><passage><infon key="section_type">ACK_FUND</infon><infon key="type">paragraph</infon><offset>34795</offset><text>No ethical approval was required for this systematic review with meta‐analysis, as all data were already published in peer‐reviewed journals. None of the patients were involved in the design, conduct or interpretation of our study. The datasets used in this study can be found in the full‐text articles included in the systematic review and meta‐analysis.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>35159</offset><text>Conflicts of Interest</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>35181</offset><text>The authors declare no conflicts of interest.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>35227</offset><text>Supporting information</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>35250</offset><text>Data Availability Statement</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>35278</offset><text>All data relevant to the study are included in the study or have been uploaded as supplementary information available online. The data supporting this systematic review and meta‐analysis are drawn from studies previously published in the literature and referenced accordingly. The processed data are available in the paper and the Supporting information S1.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>35639</offset><text>References</text></passage><passage><infon key="elocation-id">e065186</infon><infon key="issue">3</infon><infon key="section_type">REF</infon><infon key="source">BMJ Open</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2023</infon><offset>35650</offset><text>Global, Regional and National Burden of Inflammatory Bowel Disease in 204 Countries and Territories From 1990 to 2019: A Systematic Analysis Based on the Global Burden of Disease Study 2019</text></passage><passage><infon key="fpage">1550</infon><infon key="issue">6</infon><infon key="lpage">1560</infon><infon key="pub-id_pmid">15168366</infon><infon key="section_type">REF</infon><infon key="source">Gastroenterology</infon><infon key="type">ref</infon><infon key="volume">126</infon><infon key="year">2004</infon><offset>35840</offset><text>Inflammatory Bowel Diseases in Pediatric and Adolescent Patients: Clinical, Therapeutic, and Psychosocial Considerations</text></passage><passage><infon key="fpage">3147</infon><infon key="issue">10</infon><infon key="lpage">3152</infon><infon key="pub-id_pmid">32147199</infon><infon key="section_type">REF</infon><infon key="source">Clinical Nutrition</infon><infon key="type">ref</infon><infon key="volume">39</infon><infon key="year">2020</infon><offset>35961</offset><text>Total and Activity‐Induced Energy Expenditure Measured During a Year in Children With Inflammatory Bowel Disease in Clinical Remission Remain Lower Than in Healthy Controls</text></passage><passage><infon key="fpage">991</infon><infon key="issue">10</infon><infon key="lpage">1004</infon><infon key="pub-id_pmid">25783784</infon><infon key="section_type">REF</infon><infon key="source">Alimentary Pharmacology &amp; Therapeutics</infon><infon key="type">ref</infon><infon key="volume">41</infon><infon key="year">2015</infon><offset>36136</offset><text>Sleep and Physical Activity Measured by Accelerometry in Crohn's Disease</text></passage><passage><infon key="fpage">1562</infon><infon key="issue">11</infon><infon key="lpage">1568</infon><infon key="pub-id_pmid">18478564</infon><infon key="section_type">REF</infon><infon key="source">Inflammatory Bowel Diseases</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2008</infon><offset>36209</offset><text>Sarcopenia Is Prevalent in Patients With Crohn's Disease in Clinical Remission</text></passage><passage><infon key="fpage">580</infon><infon key="issue">2</infon><infon key="lpage">595</infon><infon key="pub-id_pmid">36064826</infon><infon key="section_type">REF</infon><infon key="source">Digestive Diseases and Sciences</infon><infon key="type">ref</infon><infon key="volume">68</infon><infon key="year">2023</infon><offset>36288</offset><text>Evaluation of Nutritional Characteristics Reveals Similar Prevalence of Malnutrition in Patients With Ulcerative Colitis and Crohn's Disease</text></passage><passage><infon key="fpage">1276</infon><infon key="issue">8</infon><infon key="lpage">1291</infon><infon key="pub-id_pmid">37352818</infon><infon key="section_type">REF</infon><infon key="source">Clinical Nutrition</infon><infon key="type">ref</infon><infon key="volume">42</infon><infon key="year">2023</infon><offset>36429</offset><text>Systematic Review of Sarcopenia in Inflammatory Bowel Disease</text></passage><passage><infon key="fpage">976</infon><infon key="issue">8</infon><infon key="lpage">981</infon><infon key="pub-id_pmid">2969199</infon><infon key="section_type">REF</infon><infon key="source">American Journal of Psychiatry</infon><infon key="type">ref</infon><infon key="volume">145</infon><infon key="year">1988</infon><offset>36491</offset><text>Psychiatric Disorder in a Sample of the General Population With and Without Chronic Medical Conditions</text></passage><passage><infon key="fpage">16</infon><infon key="issue">1</infon><infon key="lpage">28</infon><infon key="pub-id_pmid">34057462</infon><infon key="section_type">REF</infon><infon key="source">British Medical Bulletin</infon><infon key="type">ref</infon><infon key="volume">138</infon><infon key="year">2021</infon><offset>36594</offset><text>Psychological Factors Associated With Inflammatory Bowel Disease</text></passage><passage><infon key="fpage">3</infon><infon key="issue">1</infon><infon key="lpage">10</infon><infon key="pub-id_pmid">35782456</infon><infon key="section_type">REF</infon><infon key="source">Sports Medicine and Health Science</infon><infon key="type">ref</infon><infon key="volume">1</infon><infon key="year">2019</infon><offset>36659</offset><text>Physical Activity, Exercise, and Chronic Diseases: A Brief Review</text></passage><passage><infon key="fpage">53</infon><infon key="issue">1</infon><infon key="lpage">72</infon><infon key="pub-id_pmid">29108826</infon><infon key="section_type">REF</infon><infon key="source">Autoimmunity Reviews</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2018</infon><offset>36725</offset><text>Physical Activity and Autoimmune Diseases: Get Moving and Manage the Disease</text></passage><passage><infon key="section_type">REF</infon><infon key="source">Cochrane Handbook for Systematic Reviews of Interventions Version 6.4</infon><infon key="type">ref</infon><infon key="year">2023</infon><offset>36802</offset></passage><passage><infon key="elocation-id">105906</infon><infon key="pub-id_pmid">33789826</infon><infon key="section_type">REF</infon><infon key="source">International Journal of Surgery</infon><infon key="type">ref</infon><infon key="volume">88</infon><infon key="year">2021</infon><offset>36803</offset><text>The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews</text></passage><passage><infon key="section_type">REF</infon><infon key="source">Citationchaser: An R Package and Shiny App for Forward and Backward Citations Chasing in Academic Searching</infon><infon key="type">ref</infon><infon key="year">2022</infon><offset>36884</offset></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2013</infon><offset>36885</offset><text>Clarivate</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2018</infon><offset>36895</offset><text>Microsoft Excel</text></passage><passage><infon key="fpage">712</infon><infon key="issue">9</infon><infon key="lpage">716</infon><infon key="pub-id_pmid">12956787</infon><infon key="section_type">REF</infon><infon key="source">ANZ Journal of Surgery</infon><infon key="type">ref</infon><infon key="volume">73</infon><infon key="year">2003</infon><offset>36911</offset><text>Methodological Index for Non‐Randomized Studies (MINORS): Development and Validation of a New Instrument</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2021</infon><offset>37018</offset><text>R: A Language and Environment for Statistical Computing</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2023</infon><offset>37074</offset><text>Meta: General Package for Meta‐Analysis</text></passage><passage><infon key="fpage">1785</infon><infon key="issue">6</infon><infon key="lpage">1805</infon><infon key="pub-id_pmid">27683581</infon><infon key="section_type">REF</infon><infon key="source">Statistical Methods in Medical Research</infon><infon key="type">ref</infon><infon key="volume">27</infon><infon key="year">2018</infon><offset>37116</offset><text>Optimally Estimating the Sample Mean From the Sample Size, Median, Mid‐Range, and/or Mid‐Quartile Range</text></passage><passage><infon key="fpage">641</infon><infon key="issue">5</infon><infon key="lpage">654</infon><infon key="pub-id_pmid">32562361</infon><infon key="section_type">REF</infon><infon key="source">Research Synthesis Methods</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">2020</infon><offset>37224</offset><text>Optimally Estimating the Sample Standard Deviation From the Five‐Number Summary</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2021</infon><offset>37306</offset><text>Chapman and Hall/CRC</text></passage><passage><infon key="fpage">55</infon><infon key="issue">1</infon><infon key="lpage">79</infon><infon key="pub-id_pmid">26332144</infon><infon key="section_type">REF</infon><infon key="source">Research Synthesis Methods</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2016</infon><offset>37327</offset><text>Methods to Estimate the Between‐Study Variance and Its Uncertainty in Meta‐Analysis</text></passage><passage><infon key="elocation-id">25</infon><infon key="pub-id_pmid">24548571</infon><infon key="section_type">REF</infon><infon key="source">BMC Medical Research Methodology</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2014</infon><offset>37415</offset><text>The Hartung–Knapp–Sidik–Jonkman Method for Random Effects Meta‐Analysis Is Straightforward and Considerably Outperforms the Standard DerSimonian–Laird Method</text></passage><passage><infon key="fpage">2693</infon><infon key="issue">17</infon><infon key="lpage">2710</infon><infon key="pub-id_pmid">12939780</infon><infon key="section_type">REF</infon><infon key="source">Statistics in Medicine</infon><infon key="type">ref</infon><infon key="volume">22</infon><infon key="year">2003</infon><offset>37583</offset><text>Improved Tests for a Random Effects Meta‐Regression With a Single Covariate</text></passage><passage><infon key="fpage">1379</infon><infon key="issue">11</infon><infon key="lpage">1389</infon><infon key="pub-id_pmid">28378342</infon><infon key="section_type">REF</infon><infon key="source">Alimentary Pharmacology &amp; Therapeutics</infon><infon key="type">ref</infon><infon key="volume">45</infon><infon key="year">2017</infon><offset>37661</offset><text>Randomised Clinical Trial: Yoga Vs Written Self‐Care Advice for Ulcerative Colitis</text></passage><passage><infon key="fpage">29</infon><infon key="issue">1</infon><infon key="pub-id_pmid">30755154</infon><infon key="section_type">REF</infon><infon key="source">BMC Gastroenterology</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">2019</infon><offset>37746</offset><text>Moderate‐Intensity Aerobic and Resistance Exercise Is Safe and Favorably Influences Body Composition in Patients With Quiescent Inflammatory Bowel Disease: A Randomized Controlled Cross‐Over Trial</text></passage><passage><infon key="fpage">964</infon><infon key="issue">6</infon><infon key="lpage">975</infon><infon key="pub-id_pmid">33119156</infon><infon key="section_type">REF</infon><infon key="source">Alimentary Pharmacology &amp; Therapeutics</infon><infon key="type">ref</infon><infon key="volume">52</infon><infon key="year">2020</infon><offset>37947</offset><text>Randomised Clinical Trial: Combined Impact and Resistance Training in Adults With Stable Crohn's Disease</text></passage><passage><infon key="fpage">239</infon><infon key="issue">3</infon><infon key="lpage">247</infon><infon key="pub-id_pmid">25823689</infon><infon key="section_type">REF</infon><infon key="source">Digestion</infon><infon key="type">ref</infon><infon key="volume">91</infon><infon key="year">2015</infon><offset>38052</offset><text>The Impact of a Ten‐Week Physical Exercise Program on Health‐Related Quality of Life in Patients With Inflammatory Bowel Disease: A Prospective Randomized Controlled Trial</text></passage><passage><infon key="fpage">384</infon><infon key="issue">5</infon><infon key="lpage">388</infon><infon key="pub-id_pmid">17873551</infon><infon key="section_type">REF</infon><infon key="source">Clinical Journal of Sport Medicine</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2007</infon><offset>38228</offset><text>Low‐Intensity Exercise Improves Quality of Life in Patients With Crohn's Disease</text></passage><passage><infon key="fpage">36</infon><infon key="issue">1</infon><infon key="lpage">41</infon><infon key="pub-id_pmid">9649456</infon><infon key="section_type">REF</infon><infon key="source">Gastroenterology</infon><infon key="type">ref</infon><infon key="volume">115</infon><infon key="year">1998</infon><offset>38311</offset><text>Effect of a Low‐Impact Exercise Program on Bone Mineral Density in Crohn's Disease: A Randomized Controlled Trial</text></passage><passage><infon key="fpage">214</infon><infon key="issue">2</infon><infon key="lpage">221</infon><infon key="pub-id_pmid">37134004</infon><infon key="section_type">REF</infon><infon key="source">Journal of Pediatric Gastroenterology and Nutrition</infon><infon key="type">ref</infon><infon key="volume">77</infon><infon key="year">2023</infon><offset>38427</offset><text>Physical Training and Healthy Diet Improved Bowel Symptoms, Quality of Life, and Fatigue in Children With Inflammatory Bowel Disease</text></passage><passage><infon key="fpage">804</infon><infon key="issue">7</infon><infon key="lpage">813</infon><infon key="pub-id_pmid">32580666</infon><infon key="section_type">REF</infon><infon key="source">United European Gastroenterology Journal</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">2020</infon><offset>38560</offset><text>Moderate Endurance and Muscle Training Is Beneficial and Safe in Patients With Quiescent or Mildly Active Crohn's Disease</text></passage><passage><infon key="fpage">19</infon><infon key="issue">1</infon><infon key="pub-id_pmid">30696423</infon><infon key="section_type">REF</infon><infon key="source">BMC Gastroenterology</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">2019</infon><offset>38682</offset><text>High‐Intensity Interval Training and Moderate‐Intensity Continuous Training in Adults With Crohn's Disease: A Pilot Randomised Controlled Trial</text></passage><passage><infon key="elocation-id">e30386</infon><infon key="issue">34</infon><infon key="section_type">REF</infon><infon key="source">Medicine (Baltimore)</infon><infon key="type">ref</infon><infon key="volume">101</infon><infon key="year">2022</infon><offset>38830</offset><text>Effects of Nutritional Supplement and Resistance Training for Sarcopenia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Trial</text></passage><passage><infon key="fpage">99</infon><infon key="lpage">104</infon><infon key="pub-id_pmid">30477870</infon><infon key="section_type">REF</infon><infon key="source">Complementary Therapies in Medicine</infon><infon key="type">ref</infon><infon key="volume">41</infon><infon key="year">2018</infon><offset>38978</offset><text>Yoga as Adjunct Therapy for Adolescents With Inflammatory Bowel Disease: A Pilot Clinical Trial</text></passage><passage><infon key="fpage">239</infon><infon key="issue">4</infon><infon key="lpage">248</infon><infon key="pub-id_pmid">37487583</infon><infon key="section_type">REF</infon><infon key="source">Pediatric Exercise Science</infon><infon key="type">ref</infon><infon key="volume">35</infon><infon key="year">2023</infon><offset>39074</offset><text>A Pilot Study of Exercise Training for Children and Adolescents With Inflammatory Bowel Disease: An Evaluation of Feasibility, Safety, Satisfaction, and Efficacy</text></passage><passage><infon key="fpage">1749</infon><infon key="issue">12</infon><infon key="lpage">1750</infon><infon key="section_type">REF</infon><infon key="source">Journal of Crohn's &amp; Colitis</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">2014</infon><offset>39236</offset><text>Progressive Resistance Training Improves Muscle Strength in Women With Inflammatory Bowel Disease and Quadriceps Weakness</text></passage><passage><infon key="fpage">61</infon><infon key="issue">2</infon><infon key="lpage">69</infon><infon key="pub-id_pmid">34124177</infon><infon key="section_type">REF</infon><infon key="source">Inflammatory Intestinal Diseases</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">2021</infon><offset>39358</offset><text>Physical Activity in Patients With Inflammatory Bowel Disease: A Cross‐Sectional Study</text></passage><passage><infon key="fpage">335</infon><infon key="issue">3</infon><infon key="lpage">341</infon><infon key="pub-id_pmid">34210638</infon><infon key="section_type">REF</infon><infon key="source">Explore (New York, N.Y.)</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">2022</infon><offset>39447</offset><text>Evaluation of an Integrated Yoga Program in Patients With Inflammatory Bowel Disease: A Pilot Study</text></passage><passage><infon key="fpage">30</infon><infon key="lpage">39</infon><infon key="section_type">REF</infon><infon key="source">Mental Health and Physical Activity</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2017</infon><offset>39547</offset><text>Aerobic Exercise Training in Children and Adolescents With Inflammatory Bowel Disease: Influence on Psychological Functioning, Sleep and Physical Performance—An Exploratory Trial</text></passage><passage><infon key="fpage">297</infon><infon key="issue">1</infon><infon key="pub-id_pmid">31455308</infon><infon key="section_type">REF</infon><infon key="source">BMC Pediatrics</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">2019</infon><offset>39728</offset><text>Favorable Impact of Long‐Term Exercise on Disease Symptoms in Pediatric Patients With Inflammatory Bowel Disease</text></passage><passage><infon key="fpage">697</infon><infon key="issue">3</infon><infon key="lpage">703</infon><infon key="pub-id_pmid">10086654</infon><infon key="section_type">REF</infon><infon key="source">American Journal of Gastroenterology</infon><infon key="type">ref</infon><infon key="volume">94</infon><infon key="year">1999</infon><offset>39843</offset><text>The Effects of Physical Exercise on Patients With Crohn's Disease</text></passage><passage><infon key="fpage">1999</infon><infon key="issue">7</infon><infon key="lpage">2004</infon><infon key="pub-id_pmid">36319697</infon><infon key="section_type">REF</infon><infon key="source">Pediatric Research</infon><infon key="type">ref</infon><infon key="volume">93</infon><infon key="year">2023</infon><offset>39909</offset><text>Impact of an Exercise Program in Children With Inflammatory Bowel Disease in Remission</text></passage><passage><infon key="fpage">597</infon><infon key="issue">2</infon><infon key="lpage">604</infon><infon key="pub-id_pmid">32239380</infon><infon key="section_type">REF</infon><infon key="source">Digestive Diseases and Sciences</infon><infon key="type">ref</infon><infon key="volume">66</infon><infon key="year">2021</infon><offset>39996</offset><text>Improvement of Fatigue and Quality of Life in Patients With Quiescent Inflammatory Bowel Disease Following a Personalized Exercise Program</text></passage><passage><infon key="fpage">A‐369</infon><infon key="issue">5</infon><infon key="section_type">REF</infon><infon key="source">American Gastroenterological Association</infon><infon key="type">ref</infon><infon key="volume">136</infon><infon key="year">2009</infon><offset>40135</offset><text>Impact of Physical Activity on Course of Disease and Quality of Life in Patients With Crohn's Disease. Results From a Prospective Observational Randomized Study</text></passage><passage><infon key="fpage">804</infon><infon key="issue">3</infon><infon key="lpage">810</infon><infon key="pub-id_pmid">2644154</infon><infon key="section_type">REF</infon><infon key="source">Gastroenterology</infon><infon key="type">ref</infon><infon key="volume">96</infon><infon key="year">1989</infon><offset>40296</offset><text>A New Measure of Health Status for Clinical Trials in Inflammatory Bowel Disease</text></passage><passage><infon key="fpage">1571</infon><infon key="issue">8</infon><infon key="lpage">1578</infon><infon key="pub-id_pmid">8759664</infon><infon key="section_type">REF</infon><infon key="source">American Journal of Gastroenterology</infon><infon key="type">ref</infon><infon key="volume">91</infon><infon key="year">1996</infon><offset>40377</offset><text>The Short Inflammatory Bowel Disease Questionnaire: A Quality of Life Instrument for Community Physicians Managing Inflammatory Bowel Disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial</text></passage><passage><infon key="fpage">557</infon><infon key="issue">4</infon><infon key="lpage">563</infon><infon key="pub-id_pmid">12394384</infon><infon key="section_type">REF</infon><infon key="source">Journal of Pediatric Gastroenterology and Nutrition</infon><infon key="type">ref</infon><infon key="volume">35</infon><infon key="year">2002</infon><offset>40583</offset><text>The IMPACT Questionnaire: A Valid Measure of Health‐Related Quality of Life in Pediatric Inflammatory Bowel Disease</text></passage><passage><infon key="fpage">439</infon><infon key="issue">3</infon><infon key="lpage">444</infon><infon key="pub-id_pmid">1248701</infon><infon key="section_type">REF</infon><infon key="source">Gastroenterology</infon><infon key="type">ref</infon><infon key="volume">70</infon><infon key="year">1976</infon><offset>40701</offset><text>Development of a Crohn's Disease Activity Index. National Cooperative Crohn's Disease Study</text></passage><passage><infon key="fpage">514</infon><infon key="issue">8167</infon><infon key="pub-id_pmid">6102236</infon><infon key="section_type">REF</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">1</infon><infon key="year">1980</infon><offset>40793</offset><text>A Simple Index of Crohn's‐Disease Activity</text></passage><passage><infon key="fpage">439</infon><infon key="issue">4</infon><infon key="lpage">447</infon><infon key="pub-id_pmid">1678008</infon><infon key="section_type">REF</infon><infon key="source">Journal of Pediatric Gastroenterology and Nutrition</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">1991</infon><offset>40838</offset><text>Development and Validation of a Pediatric Crohn's Disease Activity Index</text></passage><passage><infon key="fpage">82</infon><infon key="issue">6666</infon><infon key="lpage">86</infon><infon key="pub-id_pmid">2563951</infon><infon key="section_type">REF</infon><infon key="source">BMJ</infon><infon key="type">ref</infon><infon key="volume">298</infon><infon key="year">1989</infon><offset>40911</offset><text>Coated Mesalazine (5‐Aminosalicylic Acid) Versus Sulphasalazine in the Treatment of Active Ulcerative Colitis: A Randomised Trial</text></passage><passage><infon key="fpage">29</infon><infon key="issue">1</infon><infon key="lpage">32</infon><infon key="pub-id_pmid">9771402</infon><infon key="section_type">REF</infon><infon key="source">Gut</infon><infon key="type">ref</infon><infon key="volume">43</infon><infon key="year">1998</infon><offset>41043</offset><text>A Simple Clinical Colitis Activity Index</text></passage><passage><infon key="elocation-id">otab007</infon><infon key="issue">1</infon><infon key="section_type">REF</infon><infon key="source">Crohn's &amp; Colitis 360</infon><infon key="type">ref</infon><infon key="volume">3</infon><infon key="year">2021</infon><offset>41084</offset><text>Full, Partial, and Modified Permutations of the Mayo Score: Characterizing Clinical and Patient‐Reported Outcomes in Ulcerative Colitis Patients</text></passage><passage><infon key="fpage">423</infon><infon key="issue">2</infon><infon key="lpage">432</infon><infon key="pub-id_pmid">17681163</infon><infon key="section_type">REF</infon><infon key="source">Gastroenterology</infon><infon key="type">ref</infon><infon key="volume">133</infon><infon key="year">2007</infon><offset>41231</offset><text>Development, Validation, and Evaluation of a Pediatric Ulcerative Colitis Activity Index: A Prospective Multicenter Study</text></passage><passage><infon key="fpage">1539</infon><infon key="issue">11</infon><infon key="lpage">1558</infon><infon key="pub-id_pmid">12111919</infon><infon key="section_type">REF</infon><infon key="source">Statistics in Medicine</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="year">2002</infon><offset>41353</offset><text>Quantifying Heterogeneity in a Meta‐Analysis</text></passage><passage><infon key="fpage">629</infon><infon key="issue">7109</infon><infon key="lpage">634</infon><infon key="pub-id_pmid">9310563</infon><infon key="section_type">REF</infon><infon key="source">BMJ</infon><infon key="type">ref</infon><infon key="volume">315</infon><infon key="year">1997</infon><offset>41400</offset><text>Bias in Meta‐Analysis Detected by a Simple, Graphical Test</text></passage><passage><infon key="elocation-id">e0278480</infon><infon key="issue">12</infon><infon key="pub-id_pmid">36454911</infon><infon key="section_type">REF</infon><infon key="source">PLoS ONE</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2022</infon><offset>41461</offset><text>Effects of Structured Exercise Programmes on Physiological and Psychological Outcomes in Adults With Inflammatory Bowel Disease (IBD): A Systematic Review and Meta‐Analysis</text></passage><passage><infon key="fpage">115</infon><infon key="issue">1</infon><infon key="pub-id_pmid">31266461</infon><infon key="section_type">REF</infon><infon key="source">BMC Gastroenterology</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">2019</infon><offset>41636</offset><text>Structured Physical Activity Interventions as a Complementary Therapy for Patients With Inflammatory Bowel Disease—A Scoping Review and Practical Implications</text></passage><passage><infon key="fpage">345</infon><infon key="issue">4</infon><infon key="lpage">351</infon><infon key="pub-id_pmid">33153926</infon><infon key="section_type">REF</infon><infon key="source">Journal of Science and Medicine in Sport</infon><infon key="type">ref</infon><infon key="volume">24</infon><infon key="year">2021</infon><offset>41797</offset><text>The Effect of Exercise Intensity on Chronic Inflammation: A Systematic Review and Meta‐Analysis</text></passage></document>
</collection>